Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897673650> ?p ?o ?g. }
- W2897673650 endingPage "1948" @default.
- W2897673650 startingPage "1941" @default.
- W2897673650 abstract "Introduction: Hepatocellular carcinoma (HCC) is one of the most frequent malignant tumors with 854,000 new cases per year and represents the second most frequent cause of cancer-death. Despite surveillance, the number of patients that are diagnosed at a stage in which they are eligible for curative treatments ranges from 30% to 60%. Advanced HCC (BCLC-C) is characterized by a median survival of 6 months. Sorafenib, the first systemic drug proven to be effective in prolonging survival of unresectable HCC, was approved by the FDA in 2007 but no second-line treatment was available for a decade for patients progressing on sorafenib. Finally, in 2016, the RESORCE trial demonstrated regorafenib as an effective second-line treatment.Areas covered: In this manuscript, the authors review the principal preclinical and clinical trials on regorafenib used in the treatment of unresectable HCC patients progressing on sorafenib and highlight both the advantages and the limitations of this drug.Expert opinion: Regorafenib is the only second-line treatment available for patients progressing on sorafenib. Despite its promising clinical application, many doubts still remain, necessitating further investigation to explore the tolerability of this drug in Child-Pugh B and sorafenib-intolerant patients, while its scarce cost-effectiveness must also be improved." @default.
- W2897673650 created "2018-10-26" @default.
- W2897673650 creator A5021461246 @default.
- W2897673650 creator A5037351183 @default.
- W2897673650 creator A5037523327 @default.
- W2897673650 creator A5063416087 @default.
- W2897673650 creator A5072646873 @default.
- W2897673650 creator A5076471646 @default.
- W2897673650 creator A5078126497 @default.
- W2897673650 creator A5090043256 @default.
- W2897673650 date "2018-10-20" @default.
- W2897673650 modified "2023-10-02" @default.
- W2897673650 title "Regorafenib: a promising treatment for hepatocellular carcinoma" @default.
- W2897673650 cites W1452946734 @default.
- W2897673650 cites W1757407923 @default.
- W2897673650 cites W1968209756 @default.
- W2897673650 cites W1971837077 @default.
- W2897673650 cites W1974791708 @default.
- W2897673650 cites W1975602357 @default.
- W2897673650 cites W2012708129 @default.
- W2897673650 cites W2021760512 @default.
- W2897673650 cites W2022665891 @default.
- W2897673650 cites W2050637252 @default.
- W2897673650 cites W2053526872 @default.
- W2897673650 cites W2062406852 @default.
- W2897673650 cites W2063767677 @default.
- W2897673650 cites W2067224679 @default.
- W2897673650 cites W2067691895 @default.
- W2897673650 cites W2076341209 @default.
- W2897673650 cites W2077250071 @default.
- W2897673650 cites W2088629624 @default.
- W2897673650 cites W2111358509 @default.
- W2897673650 cites W2112489161 @default.
- W2897673650 cites W2116922255 @default.
- W2897673650 cites W2125763124 @default.
- W2897673650 cites W2130953128 @default.
- W2897673650 cites W2132190370 @default.
- W2897673650 cites W2140765540 @default.
- W2897673650 cites W2155581805 @default.
- W2897673650 cites W2163382189 @default.
- W2897673650 cites W2179591645 @default.
- W2897673650 cites W2277004004 @default.
- W2897673650 cites W2518412951 @default.
- W2897673650 cites W2521441342 @default.
- W2897673650 cites W2522666231 @default.
- W2897673650 cites W2537836937 @default.
- W2897673650 cites W2560499218 @default.
- W2897673650 cites W2590227838 @default.
- W2897673650 cites W2612778339 @default.
- W2897673650 cites W2620790632 @default.
- W2897673650 cites W2730159658 @default.
- W2897673650 cites W2749279027 @default.
- W2897673650 cites W2754673428 @default.
- W2897673650 cites W2756675235 @default.
- W2897673650 cites W2761031851 @default.
- W2897673650 cites W2767403384 @default.
- W2897673650 cites W2791550988 @default.
- W2897673650 cites W2793546761 @default.
- W2897673650 cites W2796705567 @default.
- W2897673650 cites W2799933121 @default.
- W2897673650 cites W2802019690 @default.
- W2897673650 cites W2809889937 @default.
- W2897673650 cites W2810905077 @default.
- W2897673650 cites W2889699338 @default.
- W2897673650 cites W3143409077 @default.
- W2897673650 cites W4210955410 @default.
- W2897673650 doi "https://doi.org/10.1080/14656566.2018.1534956" @default.
- W2897673650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30345837" @default.
- W2897673650 hasPublicationYear "2018" @default.
- W2897673650 type Work @default.
- W2897673650 sameAs 2897673650 @default.
- W2897673650 citedByCount "15" @default.
- W2897673650 countsByYear W28976736502019 @default.
- W2897673650 countsByYear W28976736502020 @default.
- W2897673650 countsByYear W28976736502021 @default.
- W2897673650 countsByYear W28976736502022 @default.
- W2897673650 countsByYear W28976736502023 @default.
- W2897673650 crossrefType "journal-article" @default.
- W2897673650 hasAuthorship W2897673650A5021461246 @default.
- W2897673650 hasAuthorship W2897673650A5037351183 @default.
- W2897673650 hasAuthorship W2897673650A5037523327 @default.
- W2897673650 hasAuthorship W2897673650A5063416087 @default.
- W2897673650 hasAuthorship W2897673650A5072646873 @default.
- W2897673650 hasAuthorship W2897673650A5076471646 @default.
- W2897673650 hasAuthorship W2897673650A5078126497 @default.
- W2897673650 hasAuthorship W2897673650A5090043256 @default.
- W2897673650 hasConcept C121608353 @default.
- W2897673650 hasConcept C126322002 @default.
- W2897673650 hasConcept C143998085 @default.
- W2897673650 hasConcept C197934379 @default.
- W2897673650 hasConcept C2776248978 @default.
- W2897673650 hasConcept C2776264508 @default.
- W2897673650 hasConcept C2778019345 @default.
- W2897673650 hasConcept C2778375690 @default.
- W2897673650 hasConcept C2778695046 @default.
- W2897673650 hasConcept C526805850 @default.
- W2897673650 hasConcept C71924100 @default.
- W2897673650 hasConceptScore W2897673650C121608353 @default.